Alumis is the lead sponsor of 3 current clinical trials in our USA, Germany, Spain, Poland, South Korea, Canada, UK, India, Denmark, Mexico, Taiwan, France, Czechia, Portugal, Japan and Australia registers. None of its ClinicalTrials.gov trials is recruiting at the moment. The most common phase is Phase 2. The drugs named most often in its trials are Envudeucitinib. The most-studied condition is Plaque Psoriasis.
| Study | Phase | Status | Start | Registers |
|---|---|---|---|---|
|
Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus
NCT05966480 · ClinicalTrials.gov ↗ · SLE
Drug: Envudeucitinib |
Phase 2 | Active, closed | 2023-06 | UK, USA, India, Germany, Spain, Denmark, Poland, Mexico, South Korea, Taiwan |
|
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
NCT06846541 · ClinicalTrials.gov ↗ · Plaque Psoriasis, Psoriasis (PsO), Psoriasis
|
Phase 3 | Active, closed | 2025-01 | USA, Germany, France, Spain, Poland, Czechia, Portugal, Canada, Japan, South Korea, Australia |
|
Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis
NCT05739435 · ClinicalTrials.gov ↗ · Plaque Psoriasis
Drug: Envudeucitinib |
Phase 2 | Active, closed | 2023-01 | USA, Canada |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.
Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.
A trial with sites in more than one country appears in each of those registers.
| Sponsor | Trials |
|---|---|
| Oruka Therapeutics | 4 |
| Almirall | 2 |
| InventisBio | 2 |
Sponsors with the most current trials registered for this condition.
Alumis is the lead sponsor of 3 current trials on ClinicalTrials.gov in our USA, Germany, Spain, Poland, South Korea, Canada, UK, India, Denmark, Mexico, Taiwan, France, Czechia, Portugal, Japan and Australia registers, as of the registry sync on 27 September 2026. Completed and withdrawn studies are not counted.
Not at the moment. None of its 3 ClinicalTrials.gov trials is recruiting; they are active but closed to enrolment, not yet open, or enrolling by invitation. Only the study team can confirm whether a patient is eligible.
Its current trials name 1 drug or biological as interventions. The most frequent are Envudeucitinib (2). The number in brackets is how many of its trials name each drug.
Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.
Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 27 Sep 2026.